Growth opportunities Target expanding markets where SSI already has traction, notably the U.S., EU, and China, to accelerate expansion plans for Aixplorer MACH 30 and UltraFast technology in flagship imaging modalities such as SWE elastography.

Strategic partnerships Leverage potential acquisition and investment interest evidenced in 2018-2019 by engaging with larger medical device players or financial partners to scale manufacturing, distribution, and co-development of advanced ultrasound platforms.

Competitive positioning Differentiate with UltraFast technology and SWE capabilities validated by extensive publications; pursue sales conversations highlighting tissue stiffness imaging for breast, liver, and prostate diagnostics to win premium system deals.

Regulatory readiness Emphasize existing CE and FDA clearance in messaging to streamline procurement for hospitals and radiology centers, reducing regulatory friction for new regional deployments.

Service and scale Offer bundled value with installation, training, and local service agreements to large users and multi-site healthcare networks, leveraging global installed base to drive recurring revenue and rapid expansion.